Innovent announces 2nd BTD by NMPA for Olverembatinib for treatment of patients with SDH-deficient GIST

Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors

3M to invest nearly $150 million on expanding biopharma filtration capabilities

The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.

AstraZeneca receives CDSCO approval for Tremelimumab combination in India

Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)

Evonik launches next-generation peptide for biopharma applications

One thousand times more soluble than L-cystine at neutral pH

Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy

Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada

Kristin Judge Joins Emmes as Chief Growth Officer

Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies

Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.

Takeda to strengthen health system for rare diseases in India

These initiatives aim to improve access to healthcare for rare disease patients

Takeda pledges support to HAE patients through its ‘Sunrise patient support program’

Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support

FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS

Lucid-MS is a new drug candidate for the treatment of multiple sclerosis